Providing affordable access to new treatment for leukaemia and lymphoma

More than 920 Australians each year will benefit from affordable access to a new medicine for leukaemia and lymphoma patients. Ibrutinib (sold as Imbruvica®) would normally cost $187,390 on average per course of treatment, putting it beyond the reach of most patients. This $466 million listing on the pharmaceutical benefits scheme will save patients hundreds…

Transcript – Sky Australian Agenda interview with Paul Kelly and Peter Van Onselen

E&OE… Topics: Same sex marriage, mental health, energy policy, Turnbull Government’s new anti-drug campaign, welfare policy, private health insurance, health reform agenda, NRL and AFL finals PETER VAN ONSELEN: You’re watching Sunday Agenda, where we’ve been looking across the ditch to the New Zealand election result from last night. But there is a lot going…